NextCure, Inc. (NXTC)

US — Healthcare Sector
Peers: QTTB  PSTV  BOLD  VRCA  ANTX  JSPR  INTS  PLUR  TAOX  ITRM 

Automate Your Wheel Strategy on NXTC

With Tiblio's Option Bot, you can configure your own wheel strategy including NXTC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol NXTC
  • Rev/Share 1.382
  • Book/Share 13.3261
  • PB 1.0742
  • Debt/Equity 0.1574
  • CurrentRatio 3.7116
  • ROIC -1.7009

 

  • MktCap 35935287.0
  • FreeCF/Share -22.8514
  • PFCF -0.6622
  • PE -0.5227
  • Debt/Assets 0.0978
  • DivYield 0
  • ROE -1.0757

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 4
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Upgrade NXTC Ladenburg Thalmann Neutral Buy -- $18 Nov. 7, 2025

News

Does NextCure (NXTC) Have the Potential to Rally 107.88% as Wall Street Analysts Expect?
NXTC
Published: November 11, 2025 by: Zacks Investment Research
Sentiment: Positive

The average of price targets set by Wall Street analysts indicates a potential upside of 107.9% in NextCure (NXTC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Read More
image for news Does NextCure (NXTC) Have the Potential to Rally 107.88% as Wall Street Analysts Expect?
NextCure to Present at 24th Annual Needham Virtual Healthcare Conference
NXTC
Published: April 04, 2025 by: GlobeNewsWire
Sentiment: Neutral

BELTSVILLE, Md., April 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will present at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10th, at 8:45 am ET.

Read More
image for news NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

About NextCure, Inc. (NXTC)

  • IPO Date 2019-05-09
  • Website https://www.nextcure.com
  • Industry Biotechnology
  • CEO Michael S. Richman MSBA
  • Employees 43
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.